Archive for May, 2004

How long is it necessary to treat active SLE with immunosuppressive drugs? Can immunosuppressive therapy be discontinued? If so, when

Monday, May 24th, 2004

Ask the Expert
Michael D. Lockshin, MD

If you look in current texts, or even on this web site, you do not easily find answers to these very basic questions. The reasons clear answers are hard to come by reflect the great diversity of clinical manifestations of lupus, its proclivity to flare and remit unpredictably, and the long follow-up times necessary to demonstrate superiority of treatment protocols. The only credible studies that have addressed the issue of duration of treatment are the long-term studies initiated at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH) decades ago. In these studies, which have been periodically updated, intravenous cyclophosphamide given with prednisone monthly for 6 months followed by 2 additional years of infusions given every 3 months, or azathioprine continued for 2 years, resulted in fewer renal flares and better long-term (10 year) renal outcome than did monthly intravenous cyclophosphamide and daily oral cyclophosphamide or azathioprine for 6 months[1],[2],[3].

vasculitis and in lupus, several recent studies from England and from continental Europe now suggest that a short, 3 month, induction course of cyclophosphamide followed by azathioprine or mycophenolate mofetil (for unspecified times) result in durable remissions. These studies do not address the length of oral treatment nor very long-term outcomes; indeed, most look at outcomes at no more than 1 or 2 years. Although the vasculitis studies may have implications for non-renal SLE, no duration of immunosuppressive therapy studies exist for other non-renal manifestations of disease, for instance brain or spinal cord lupus, thrombocytopenia, or hemolytic anemia. Protocol studies with experimental agents usually treat for induction only, then await recurrence before retreating.

That said, a reasonable rule for the clinician to follow might be: in the treatment of renal lupus, immunosuppression can be withdrawn after 2 years in those patients who are clinically (and serologically?) inactive. For treatment of non-renal lupus, one can consider withdrawal of azathioprine or mycophenolate mofetil after a full year of clinical quiescence. In patients who remain clinically active with either renal or non-renal lupus, it is common practice to continue azathioprine or mycophenolate mofetil indefinitely. The cumulative toxicity of cyclophosphamide (especially marrow fibrosis, hemorrhagic cystitis, and bladder cancer) prohibits its continued use after 2 years. In the event of recurrent flare, re-treatment with any of the immunosuppressive medications is possible; multiple recurrent flares require ad hoc treatment decisions highly tailored to the specific circumstances of the patient.

See the complete article on the Hospital for Special Surgery’s web site
——————————————————————————–
[1] Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002 Apr;46(4):995-1002.

[2] Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 Aug 21;135(4):248-57.

[3] Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996 Oct 1;125(7):549-57.

An In-Depth Topic Review of Systemic Lupus Erythematosus

Thursday, May 20th, 2004

For Physicians
Michael D. Lockshin, MD

1. Definition
2. Pathogenesis
3. Clinical Presentation
4. Laboratory Findings
5. Differential Diagnosis
6. Initial Treatment
7. Long-term Management Issues
8. Prognosis
9. When to Refer

1. DefinitionLupus is both an acute and a chronic autoimmune, multisystem illness. Lupus has several forms: systemic (SLE), discoid (DLE, scarring rash only), drug-induced (DILE), and neonatal (NLE). For purposes of brevity, drug-induced lupus,[1] which is relatively rare, and discoid lupus are not discussed in this chapter.

See the complete article on the Hospital for Special Surgery’s web site

Autoimmune Disease: Does Sex Matter?

Sunday, May 2nd, 2004

Current Theories
Michael D. Lockshin, MD

With some exceptions, autoimmune diseases affect far more women than men. For some time, physicians and researchers have been asking why this is so. The most popular theory to date has been that female hormones set the stage for diseases such as systemic lupus erythematosus, Sjogren’s syndrome, and rheumatoid arthritis. But more recent research calls this theory into question-and suggests that there may be other reasons for the greater incidence of autoimmune disease in women, an issue sometimes referred to as sex predominance. Possible explanations may be roughly divided up into four areas: (1) hormone theory, (2) environmental factors, (3) genetic influences, and (4) whole organism factors.

Discussion of these potential causes is sometimes complicated by disagreement about the definition of an autoimmune disease. For the most part, however, there is general agreement that the following are autoimmune diseases: system lupus erythematosus, rheumatoid arthritis, Sjogren’s syndrome, scleroderma, primary biliary cirrhosis, chronic active hepatitis, Graves disease, Goodpasture’s disease, hemolytic anemia, idiopathic thrombocytic purpura and Hashimoto’s thyroiditis. Other diseases that many physicians would put in this category include: ankylosing spondylitis, Lyme disease, pemphigus, vitiligo, myasthenia gravis, multiple sclerosis, and juvenile onset diabetes. A number of other illnesses may have features that are similar to those of autoimmune diseases, but they are not labeled as autoimmune diseases.

Current Theories of Sex Predominance

1. Hormone Theory
Hormone theory refers to the traditional belief that estrogen production puts women at a greater risk for developing an autoimmune disease. In tests conducted in the laboratory, estrogen has been demonstrated to make women’s immune systems “over-react” when compared to men’s. This finding supports the standard definition for lupus and other auto-immune diseases, in which the immune system is said to over-react to the body’s own tissues. It also appears to explain the ratio of incidence in a disease like lupus, in which 9 women get the disease for every 1 man.

However, there are autoimmune diseases that occur more frequently in men than in women, including Goodpasture’s syndrome, in which the body creates antibodies that attack the lungs and kidneys. This disease occurs in 1 woman for every 3 men.

Another problem with the hormone theory is disease severity. If women are more likely to develop lupus because they produce estrogen, they could be expected to become more seriously ill. But, overall, men and women with lupus experience the disease with the same range of severity.

If estrogen were the deciding factor in who gets autoimmune diseases, it would also be reasonable to expect that similar diseases would have similar male-female ratios. However, there are a number of diseases that share characteristics with lupus (9:1) that have very different ratios, including Goodpasture’s disease (1:3), idiopathic thrombocytopenic purpura (2:1), and hemolytic anemia (2:1).

If hormones and immune response are linked, then one could also expect women to react differently than men to infections and immunizations. However, there appears to be no significant difference. Moreover, hormonal changes that occur when menstruation begins, during pregnancy, and with menopause, do not seem to affect the course of autoimmune disease. Neither does the use of birth control pills or hormone replacement therapy.

2. Environmental Factors
As these arguments against the role of hormones in explaining sex predominance and autoimmune disease have become more widely discussed, researchers are paying more attention to environmental factors. Some diseases that have been classified as autoimmune diseases are clearly caused by exposure to external toxins — medications or environmental pollutants. The differing roles of men and women at home and in the workplace help to explain who is exposed to these toxins.

Scleroderma, for example, is seen disproportionately in male gold and coal miners who are exposed to high levels of silica. Drug-induced lupus is a long-recognized disease that occurred in the 1960s and 1970s, mostly in men who were given certain drugs to treat heart disease, and still occurs today, but less often since better drugs are available.

Other examples of autoimmune disease caused by exposure include an epidemic of a disease that resembled scleroderma in Spain in the 1970s. In this case, 10,000 people, mostly women who were cooking at home with contaminated oil, developed the illness. While both men and women ate the cooked foods, women tasted the food as it was cooking, at a point when the heat had not yet destroyed the contaminant. By the time the food reached the table, the contaminant was destroyed, and no longer harmful.

In another instance, men who cleaned manufacturing vats used to make polyvinyl chloride (the plastic that is used in so many products that we use on a daily basis) developed scleroderma. It was later found that they were exposed to a monomer in the air, a toxic chemical compound that joins with other compounds during heating to become polyvinyl chloride.

The role of environmental factors may also be seen in children. In those under 12, for example, more boys develop Lyme disease than do girls. The reason for this difference can be found in the way children play. More boys play outside more of the time, and in doing so, increase their risk of exposure to disease-carrying ticks in wooded areas. (Looking at this example, one could come to the conclusion that a preference for a certain type of activity might be determined by hormones, which in turn could influence exposure to the environmental factor.)

In an area of Brazil, a disease that closely resembles pemphigus foliaceus, an autoimmune skin disorder characterized by blisters, has been associated with a certain kind of black fly that lives near the river. Men who fished in this river were more likely to develop the disease than women who had less exposure to the flies.

These examples support the idea that exposure to a toxin determines who will develop the disease, rather than the sex of the patient. Unfortunately, it does not yet help to explain female predominance in a disease like systemic lupus erythematosus. Researchers have looked at exposure to a number of products that women use with greater frequency, such as hair dye and lipstick, but have not identified any cause-and-effect link.

The role of behavior can also be considered to influence the development of disease. Examples include osteoporosis, which can be modified by doing weight-bearing exercise. Coronary disease, including strokes and atherosclerosis, can be affected by changes in diet and reduction of cholesterol levels. And, injury-related osteoarthritis risk can be reduced by avoiding extreme sports. The risk of developing Reiter’s disease-a kind of reactive arthritis sometimes caused by venereal disease-can also be reduced by modifying behavior.

It seems clear therefore, that behavior can cause illness, but we haven’t identified the specific behaviors involved with most autoimmune diseases.

3. Genetic Influences
Genetic differences between men and women have also been considered as an explanation for why one sex gets a disease more frequently than the other. Researchers have learned some interesting facts about these differences. Among them:

• Every cell in every man’s body is different from every cell in every woman’s body-even those found in identical tissues (e.g., a man’s liver and a woman’s liver).
• There are huge differences in the DNA between the sexes, the cell membranes, and the way cells associate in the body. For example, every woman gets X chromosomes from her mother and her father. Every man gets X chromosomes from his mother only (he gets the Y chromosome from his father.)
• Women who have been pregnant carry their baby’s cells in their bloodstream even after they have given birth to their children-sometimes for decades. In normal women the cells drop dramatically after birth. In women with autoimmune diseases, the cells are often present at much higher numbers for a much longer period of time. These diseases include: scleroderma, primary biliary cirrhosis, Sjogren’s syndrome, and autoimmune thyroid disease. In women with thyroid nodules, the cells within the nodules have been found to be male cells, while the rest of the thyroid is made up of female cells.

As fascinating as this information is, scientists have not yet figured out its significance. But we can expect much more study of these phenomena.

4. Whole organism Issues
Whole organism issues may also be a part of the picture-those that have nothing to do with sex or genes. For example, osteoporosis is, in large part dictated by body size. Very heavy people don’t get it, very thin people do. Moreover, tall, heavy people are less likely to have osteoporosis than are small, heavy people, since the disease relates to the size of the bones and how much calcium is lost from them. The likelihood of a woman developing breast cancer may be influenced by how many children she has, and Alzheimer’s disease appears to be linked with aging, although it is not understood whether it is part of the process itself, or something that takes 60 or 70 years to develop. Study of the aging process and autoimmune disease is underway as well. Can signs of the disease be detected in the bloodstream well before the patient has any symptoms? And, if so, are there ways to slow the progress of the disease or stop it?

Looking at all of these factors, Dr. Lockshin concludes that a variety of factors may explain why more women get autoimmune diseases than do men. Why is there a 9 to 1 ratio in a disease like lupus? Why does rheumatoid arthritis occur in 2 women for every one man? Why do more men than women develop Goodpasture’s syndrome? It could be environment, hormones, behavior, genetic differences, or a combination of some or all of these factors. The information available to us now is part of a continuing discussion that promises to yield new ways of thinking about and approaching autoimmune disease over the coming decade and beyond.

Additional Reading
If you are interested in reading more about the relationship between sex and disease, you may be interested in the following:

Exploring the Biological Contributions to Human Health: Does Sex Matter? This book compiles a vast range of writings on the role of sex in a range of diseases, not just autoimmune illnesses. It is available for purchase or for free on-line at www.nap.edu/catalog/10028.html

The X in Sex: How the X Chromosome Controls Our Lives by David Bainbridge. Available in bookstores and through on-line booksellers.

Y: The Descent of Men by Steve Jones. Available in bookstores and through on-line booksellers.

See the complete article on the Hospital for Special Surgery’s web site
Summary prepared by Nancy Novick.